A MULTI-CENTER, OPEN-LABEL, SINGLE-ARM PHASE II TRIAL OF BENDAMUSTINE, RITUXIMAB AND THE SECOND GENERATION BTK INHIBITOR ACALABRUTINIB IN PREVIOUSLY UNTREATED WALDENSTROM¿S MACROGLOBULINEMIA (BRAWM)

Registry ID
3242
Source registry
HEALTH_CANADA
Status
Ongoing
Phase
PHASE2
Study type
INTERVENTIONAL
Sponsor
SUNNYBROOK RESEARCH INSTITUTE
Start date
2022-03-08
Last update
2020-09-03

Conditions

View on source registry